دورية أكاديمية
أعرض في EDS

REal-world treatment outcomes after delayed intRavitreal therapy in center-involving diabetic macular edema - RETORT study.

التفاصيل البيبلوغرافية
العنوان: REal-world treatment outcomes after delayed intRavitreal therapy in center-involving diabetic macular edema - RETORT study.
المؤلفون: Chitturi SP; Dept. of Retina and Vitreous, Narayana Nethralaya, #121/C, 1st R Block, Chord Road, Rajaji Nagar, 560010, Bengaluru, Karnataka, India., Venkatesh R; Dept. of Retina and Vitreous, Narayana Nethralaya, #121/C, 1st R Block, Chord Road, Rajaji Nagar, 560010, Bengaluru, Karnataka, India. vramesh80@yahoo.com., Mangla R; Dept. of Retina and Vitreous, Narayana Nethralaya, #121/C, 1st R Block, Chord Road, Rajaji Nagar, 560010, Bengaluru, Karnataka, India., Parmar Y; Dept. of Retina and Vitreous, Narayana Nethralaya, #121/C, 1st R Block, Chord Road, Rajaji Nagar, 560010, Bengaluru, Karnataka, India., Sangoram R; Dept. of Retina and Vitreous, Narayana Nethralaya, #121/C, 1st R Block, Chord Road, Rajaji Nagar, 560010, Bengaluru, Karnataka, India., Yadav NK; Dept. of Retina and Vitreous, Narayana Nethralaya, #121/C, 1st R Block, Chord Road, Rajaji Nagar, 560010, Bengaluru, Karnataka, India., Chhablani J; Medical Retina and Vitreoretinal Surgery, University of Pittsburgh School of Medicine, 203 Lothrop Street, Suite 800, Pittsburg, PA, 15213, USA.
المصدر: International journal of retina and vitreous [Int J Retina Vitreous] 2023 Mar 30; Vol. 9 (1), pp. 22. Date of Electronic Publication: 2023 Mar 30.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 101677897 Publication Model: Electronic Cited Medium: Print ISSN: 2056-9920 (Print) Linking ISSN: 20569920 NLM ISO Abbreviation: Int J Retina Vitreous Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: London : BioMed Central, [2015]-
مستخلص: Purpose: To compare real-life data on delayed intravitreal treatment of diabetic macular edema (DME) patients to early treatment.
Methods: In this single-centre, retrospective, interventional, comparative study, DME patients were divided into two groups based on when they received treatment: Group 1 - received treatment within 24 weeks and Group 2 - at or after 24 weeks from the time of treatment advice. Visual acuity and central subfield thickness (CSFT) changes were compared at various time points. Reasons for delaying treatment were noted.
Results: The study included 109 (Group 1-94; Group 2-15) eyes. When treatment was advised, demographic profile, diabetes duration, glucose control and VA between two groups were comparable. At this point, CSFT was higher in Group 1 than in Group 2 (p = 0.036). At injection time, Group 2 had better VA and lower CSFT than Group 1 (p < 0.05). Group 2's VA (53.4 ± 12.67) was significantly lower than Group 1's (57.38 ± 20.01) after 1-year treatment. At 1-year, CSFT decreased in Group 1 and increased in Group 2. Group 1 had mean improvement of + 7.6 letters and Group 2 had a decline of -6.9 letters. Group 2 required more intravitreal anti-VEGF (median - 3; IQR: 2-4), steroid injections (median - 4; IQR: 2-4) and focal laser sessions (median - 4; IQR: 2-4).
Conclusion: Late-treated DME eyes needed more injections and focal laser sessions than early treated eyes. Adherence to early treatment of DME in real-life will help prevent long-term vision loss.
(© 2023. The Author(s).)
References: Retina. 2018 Dec;38(12):2293-2300. (PMID: 29068914)
Retina. 2009 Nov-Dec;29(10):1436-43. (PMID: 19898182)
Sci Rep. 2021 Sep 27;11(1):19100. (PMID: 34580364)
Lancet Diabetes Endocrinol. 2019 Feb;7(2):140-149. (PMID: 30005958)
Retina. 2010 Jul-Aug;30(7):1046-50. (PMID: 20559157)
Ophthalmology. 2015 Jul;122(7):1395-401. (PMID: 25870079)
Indian J Ophthalmol. 2018 Dec;66(12):1736-1750. (PMID: 30451174)
N Engl J Med. 2015 Mar 26;372(13):1193-203. (PMID: 25692915)
Curr Opin Ophthalmol. 2017 Nov;28(6):636-643. (PMID: 28837425)
Invest Ophthalmol Vis Sci. 2014 May 08;55(5):3361-7. (PMID: 24812554)
Rom J Ophthalmol. 2015 Jul-Sep;59(3):133-6. (PMID: 26978879)
Diabetes Metab Syndr Obes. 2022 Feb 09;15:395-405. (PMID: 35177916)
Ophthalmology. 2003 Sep;110(9):1677-82. (PMID: 13129861)
Ophthalmology. 2007 Mar;114(3):525-36. (PMID: 17123615)
Clin Ophthalmol. 2022 Aug 24;16:2797-2801. (PMID: 36042912)
J Diabetes Res. 2016;2016:2156273. (PMID: 27761468)
JCI Insight. 2017 Jul 20;2(14):. (PMID: 28724805)
Taiwan J Ophthalmol. 2019 Dec 13;9(4):233-242. (PMID: 31942428)
Retina. 2017 Nov;37(11):2015-2024. (PMID: 28092342)
Ophthalmology. 2015 Jul;122(7):1375-94. (PMID: 25935789)
Am J Ophthalmol. 2022 Jun;238:157-172. (PMID: 35038415)
Eye Vis (Lond). 2015 Sep 30;2:17. (PMID: 26605370)
Indian J Ophthalmol. 2021 Nov;69(11):3076-3086. (PMID: 34708746)
Am J Ophthalmol. 2016 Apr;164:57-68. (PMID: 26802783)
J Korean Med Sci. 2018 Jun 26;33(34):e213. (PMID: 30127705)
Invest Ophthalmol Vis Sci. 2008 Nov;49(11):5041-7. (PMID: 18539929)
Acta Diabetol. 2019 Jul;56(7):777-784. (PMID: 30903434)
Acta Ophthalmol. 2022 Mar;100(2):e546-e552. (PMID: 34145756)
JAMA. 2019 May 21;321(19):1880-1894. (PMID: 31037289)
Graefes Arch Clin Exp Ophthalmol. 2012 Jan;250(1):61-70. (PMID: 21874345)
فهرسة مساهمة: Keywords: Compliance; Delayed treatment; Diabetic macular edema; Early treatment; Outcomes
تواريخ الأحداث: Date Created: 20230330 Latest Revision: 20230401
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC10061690
DOI: 10.1186/s40942-023-00463-y
PMID: 36998064
قاعدة البيانات: MEDLINE
الوصف
تدمد:2056-9920
DOI:10.1186/s40942-023-00463-y